HC Wainwright Reaffirms “Buy” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $17.50 target price on the stock.

Several other analysts also recently weighed in on the stock. Robert W. Baird dropped their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday. Barclays dropped their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.36.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $0.83 on Friday. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.14. The firm has a 50 day moving average price of $0.80 and a 200 day moving average price of $1.08. The company has a market capitalization of $57.05 million, a PE ratio of -0.48 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). As a group, equities research analysts forecast that Vor Biopharma will post -1.51 earnings per share for the current year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its position in Vor Biopharma by 51.4% in the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after acquiring an additional 27,597 shares during the last quarter. Hsbc Holdings PLC lifted its position in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after acquiring an additional 31,333 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Vor Biopharma in the second quarter valued at $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vor Biopharma in the second quarter valued at $63,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.